FDA Adverse Event Malfunction Summary report: N

ROCHE DIAGNOSTICS COBAS ELECSYS ANTI-TPO

MDR report key: 11634003 · Received April 8, 2021

Report

Report Number
1823260-2021-01073
Event Type
Malfunction
Date Received
April 8, 2021
Date of Event
March 11, 2021
Report Date
April 28, 2021
Manufacturer
ROCHE DIAGNOSTICS
Product Code
JZO
PMA / PMN Number
K051890
Removal / Correction Number
NA
Product Problem
Yes
Report Source
Manufacturer report
Reporter Location
JA
Reporter Occupation
OTHER HEALTH CARE PROFESSIONAL

Narratives

Additional Manufacturer Narrative · 0

A GENERAL PRODUCT ISSUE CAN BE EXCLUDED. THE NEGATIVE AUTOANTIBODY RESULTS MATCH WITH THE RESULTS GENERATED WITH ABBOTT ARCHITECT. THE RESPECTIVE METHODS ARE IN THE SAME RANGE IN RELATION TO THE REFERENCE VALUES AND THEREWITH HAVE THE SAME CLINICAL INTERPRETATION. A REAGENT ISSUE OR INTERFERING FACTORS AFFECTING ELECSYS ASSAYS CAN BE EXCLUDED.

Additional Manufacturer Narrative · 1

UDI NUMBER = (B)(4). THIS EVENT OCCURRED IN (B)(6).

Description of Event or Problem · 1

THE INITIAL REPORTER STATED THEY RECEIVED QUESTIONABLE RESULTS FOR ONE PATIENT SAMPLE TESTED WITH ROCHE DIAGNOSTICS COBAS ELECSYS ANTI-TPO ON A COBAS 8000 E 801 MODULE. THE RESULTS OBTAINED WITH THE ROCHE METHOD AND A COMPETITOR METHOD DID NOT AGREE WITH THE CLINICAL PICTURE OF THE PATIENT. IT IS NOT KNOWN IF ANY INCORRECT RESULTS WERE REPORTED OUTSIDE OF THE LABORATORY. THE SAMPLE WAS TESTED FOR OTHER PARAMETERS ON THE CUSTOMER'S ANALYZER AND THEN SENT FOR INVESTIGATION. DURING INVESTIGATIONS, THE SAMPLE WAS TESTED ON AN E 801 ANALYZER, RESULTING IN AN ANTI-TPO VALUE OF < 9.00 IU/ML (REFERENCE RANGE = < 30 IU/ML). THE SAMPLE WAS ALSO TESTED ON AN ABBOTT ARCHITECT ANALYZER, RESULTING IN AN ANTI-TPO VALUE OF < 0.50 IU/ML (REFERENCE RANGE = < 5.61 IU/ML). THE SERIAL NUMBER OF THE E 801 ANALYZER IS (B)(4).

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
531614 ROCHE DIAGNOSTICS COBAS ELECSYS ANTI-TPO SYSTEM, TEST, THYROID AUTOANTIBODY JZO ROCHE DIAGNOSTICS NA 522679

Patients

Seq Age Sex Outcome Treatment
1